Breaking News Instant updates and real-time market news.

ALKS

Alkermes

$18.42

0.01 (0.05%)

07:14
10/23/19
10/23
07:14
10/23/19
07:14

Alkermes sees ALKS 3831 NDA for schizophrenia, bipolar I this quarter

Alkermes CEO Richard Pops says in today's earnings statement, "As the profile of Alkermes changes, our executional priorities are clear: maximize the value of our commercial products and development candidates, streamline our cost structure and position the company for sustained future profitability. The restructuring is designed to further focus our R&D efforts on specific high-potential programs within CNS and oncology, improve financial efficiencies in our SG&A organization and drive growth. VIVITROL and ARISTADA provide a strong and growing foundation for our commercial business and the anticipated commercial launch of VUMERITY will provide a profitable new source of royalty revenues. We also continue to advance our pipeline programs, with the planned submission of the ALKS 3831 New Drug Application for both schizophrenia and bipolar I disorder this quarter, and the planned presentation of new data from ALKS 4230, our phase 1/2 immuno-oncology asset, at an upcoming medical meeting."

  • 23

    Oct

  • 06

    Nov

ALKS Alkermes
$18.42

0.01 (0.05%)

07/30/19
HCWC
07/30/19
NO CHANGE
Target $28
HCWC
Neutral
Alkermes settlement close to best-case scenario, says H.C. Wainwright
H.C. Wainwright analyst Douglas Tsao says Alkermes' (ALKS) settlement and license agreement with Amneal Pharmaceuticals (AMRX) provides a "measure of needed visibility." There was some investor nervousness coming into the hearing and this settlement "represents close to a best-case scenario for Alkermes," Tsao tells investors in a research note. Vivitrol's growth has slowed but 12% volume growth in Q2 indicates the franchise can continue to be a contributor for the foreseeable future, adds the analyst. Tsao thinks the bull thesis for Alkermes hinges largely on the prospects for ALKS-4230. The update that patients on ALKS-4230 appear to avoid capillary leak syndrome, which has limited the utility of IL-2 therapies in the past, is important, according to Tsao. He keeps a Neutral rating on Alkermes with a $28 price target.
07/30/19
JPMS
07/30/19
NO CHANGE
JPMS
Overweight
Alkermes, Biogen data a positive, but questions remain, says JPMorgan
JPMorgan analyst Cory Kasimov views the data this morning from Alkermes (ALKS) and Biogen (BIIB) as an incremental positive but he believes commercial questions remain for Vumerity. The analyst has an Overweight rating on Alkermes and Neutral rating on Biogen. How doctors will view this dataset and how aggressive Biogen will be in launching Vumerity in the face of questions regarding Tecfidera's ultimate runway are the next key questions, Kasimov tells investors in a research note. However, he calls this morning's news a "good-to-see outcome."
07/30/19
PIPR
07/30/19
NO CHANGE
PIPR
Neutral
Piper says Alkermes scores 'back-to-back wins' with settlement, Biogen data
Piper Jaffray analyst Danielle Brill said Alkermes (ALKS) has scored "back-to-back wins" with its announcement yesterday that it settled the ongoing Vivitrol patent dispute with Amneal (AMRX) and the news this morning that BIIB098 showed a statistically significant improvement on GI tolerability versus Tecfidera in a head-to-head Phase 3 trial. She still questions how meaningful the improvement in GI tolerability actually is, but thinks the drug may become a priority for partner Biogen (BIIB), Brill tells investors. The analyst, who views the news of the last two days as net positive for Alkermes, maintains her concerns about long-term value creation and the company's "dry pipeline," she said. Brill keeps a Neutral rating on Alkermes shares.
09/05/19
MSCO
09/05/19
UPGRADE
Target $20
MSCO
Equal Weight
Alkermes upgraded to Equal Weight from Underweight at Morgan Stanley
Morgan Stanley analyst David Risinger upgraded Alkermes to Equal Weight from Underweight while lowering his price target for the shares to $20 from $30. The stock has underperformed, and recent developments eliminated the worst-case scenarios for Vumerity trial results and Vivitrol's patent, Risinger tells investors in a research note. Although cancer pipeline candidate ALKS 4230 could still disappoint, consensus expectations are low due to a questionable profile, adds the analyst. He believes Alkermes' long-term risk to royalty streams is balanced by its pipeline or cost savings optionality at current share levels.

TODAY'S FREE FLY STORIES

ULTA

Ulta Beauty

$244.06

2.19 (0.91%)

21:19
11/12/19
11/12
21:19
11/12/19
21:19
Initiation
Ulta Beauty initiated  »

Ulta Beauty initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

TJX

TJX

$58.40

-0.14 (-0.24%)

21:15
11/12/19
11/12
21:15
11/12/19
21:15
Initiation
TJX initiated  »

TJX initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

TPR

Tapestry

$26.38

-0.295 (-1.11%)

21:12
11/12/19
11/12
21:12
11/12/19
21:12
Initiation
Tapestry initiated  »

Tapestry initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

AFL

Aflac

$53.97

-0.04 (-0.07%)

21:02
11/12/19
11/12
21:02
11/12/19
21:02
Hot Stocks
Aflac names Frederick Crawford new COO »

Aflac announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROST

Ross Stores

$110.97

-1.16 (-1.03%)

21:00
11/12/19
11/12
21:00
11/12/19
21:00
Initiation
Ross Stores initiated  »

Ross Stores initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

RL

Ralph Lauren

$111.44

-2.58 (-2.26%)

20:57
11/12/19
11/12
20:57
11/12/19
20:57
Initiation
Ralph Lauren initiated  »

Ralph Lauren initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RH

RH

$174.48

-0.18 (-0.10%)

20:56
11/12/19
11/12
20:56
11/12/19
20:56
Initiation
RH initiated  »

RH initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PVH

PVH Corp.

$96.91

0.14 (0.14%)

20:53
11/12/19
11/12
20:53
11/12/19
20:53
Initiation
PVH Corp. initiated  »

PVH Corp. initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

JWN

Nordstrom

$36.90

-0.52 (-1.39%)

20:51
11/12/19
11/12
20:51
11/12/19
20:51
Initiation
Nordstrom initiated  »

Nordstrom initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

NKE

Nike

$89.51

-0.52 (-0.58%)

20:46
11/12/19
11/12
20:46
11/12/19
20:46
Initiation
Nike initiated  »

Nike initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EYE

National Vision

$27.03

0.24 (0.90%)

20:43
11/12/19
11/12
20:43
11/12/19
20:43
Initiation
National Vision initiated  »

National Vision initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LB

L Brands

$17.53

0.02 (0.11%)

20:40
11/12/19
11/12
20:40
11/12/19
20:40
Initiation
L Brands initiated  »

L Brands initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

BABA

Alibaba

$186.97

0.26 (0.14%)

20:25
11/12/19
11/12
20:25
11/12/19
20:25
Periodicals
Alibaba gets approval to sell shares in Hong Kong, SCMP reports »

Alibaba has received…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

ENR

Energizer

$42.01

-1.1 (-2.55%)

, SPB

Spectrum Brands

$51.19

-0.76 (-1.46%)

20:25
11/12/19
11/12
20:25
11/12/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

ENR

Energizer

$42.01

-1.1 (-2.55%)

SPB

Spectrum Brands

$51.19

-0.76 (-1.46%)

SSYS

Stratasys

$20.74

0.04 (0.19%)

FVRR

Fiverr

$21.56

-0.47 (-2.13%)

MTOR

Meritor

$23.44

-0.25 (-1.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 21

    Nov

  • 09

    Dec

  • 12

    Dec

DDOG

Datadog

$34.40

0.89 (2.66%)

20:02
11/12/19
11/12
20:02
11/12/19
20:02
Hot Stocks
Datadog establishes Japanese subsidiary »

Datadog announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 19

    Nov

NKE

Nike

$89.51

-0.52 (-0.58%)

, AMZN

Amazon.com

$1,778.33

6.63 (0.37%)

19:40
11/12/19
11/12
19:40
11/12/19
19:40
Periodicals
Nike says to end retail pilot project w/ Amazon.com but continue AWS partnership 

Report from Bloomberg.

NKE

Nike

$89.51

-0.52 (-0.58%)

AMZN

Amazon.com

$1,778.33

6.63 (0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 14

    Nov

  • 15

    Nov

  • 19

    Nov

  • 20

    Nov

HPE

HP Enterprise

$17.34

-0.11 (-0.63%)

, FJTSY

Fujitsu

$0.00

(0.00%)

19:34
11/12/19
11/12
19:34
11/12/19
19:34
Hot Stocks
HP Enterprise's Cray to partner with Fujitsu on 'supercomputer' technology »

Cray, a Hewlett Packard…

HPE

HP Enterprise

$17.34

-0.11 (-0.63%)

FJTSY

Fujitsu

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Nov

  • 09

    Dec

  • 09

    Dec

  • 10

    Dec

IMAX

Imax

$21.26

-0.62 (-2.83%)

19:23
11/12/19
11/12
19:23
11/12/19
19:23
Hot Stocks
Imax names Edwin Tan as CEO of Imax China »

IMAX China announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 20

    Nov

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$308.96

0.57 (0.18%)

19:21
11/12/19
11/12
19:21
11/12/19
19:21
Periodicals
Tariffs on China imports become stumbling block to trade pact, WSJ says »

Tariffs are emerging as…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$308.96

0.57 (0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHK

Chesapeake

$0.67

-0.138 (-17.08%)

19:19
11/12/19
11/12
19:19
11/12/19
19:19
Hot Stocks
Chesapeake CEO says 'strongly' believes in current capital program »

November 12, 2019,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$1,298.77

0.01 (0.00%)

, GOOGL

Alphabet Class A

$1,297.18

-0.8 (-0.06%)

19:17
11/12/19
11/12
19:17
11/12/19
19:17
Periodicals
HHS opens federal probe into Google's 'Project Nightingale,' WSJ reports »

The Office for Civil…

GOOG

Alphabet

$1,298.77

0.01 (0.00%)

GOOGL

Alphabet Class A

$1,297.18

-0.8 (-0.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SBUX

Starbucks

$83.30

1.27 (1.55%)

19:10
11/12/19
11/12
19:10
11/12/19
19:10
Hot Stocks
Starbucks unveils 35,000 sq foot reserve roastery in Chicago. »

Starbucks unveiled…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLD

SPDR Gold Shares

$137.42

0.37 (0.27%)

19:00
11/12/19
11/12
19:00
11/12/19
19:00
Hot Stocks
SPDR Gold Shares holdings fall to 897.09MT from 901.19MT »

This is the lowest level…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTE

PolarityTE

$2.89

-0.41 (-12.42%)

18:57
11/12/19
11/12
18:57
11/12/19
18:57
Recommendations
PolarityTE analyst commentary at Piper Jaffray »

PolarityTE price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

DK

Delek US

$38.45

-0.06 (-0.16%)

18:51
11/12/19
11/12
18:51
11/12/19
18:51
Hot Stocks
Delek US CFO sells 50K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.